Treatment of patients with nonalcoholic fatty liver has typically been focused on the management of associated conditions such as obesity, diabetes mellitus, and hyperlipidemia as well as discontinuation of potentially hepatotoxic drugs.
Introduction
Nonalcoholic fatty liver (NAFL) is a medical condition that may progress to end-stage liver disease with the consequent development of portal hypertension and liver failure.[1, [2] ] In some patients, however, NAFL follows a relatively benign course and remains stable for many years, and it will probably never progress in some others. [3,[4] ] Thus, the decision to intervene with medical therapy should be aimed at arresting disease progression and, ideally, be restricted to the NAFL patients at risk of developing advanced liver disease. Unfortunately, because the natural history of NAFL remains unknown and risk factors to predict disease progression over time (Table 1) . Other liver diseases including viral or autoimmune hepatitis and metabolic or hereditary liver diseases should be appropriately excluded.
Because the pathogenesis of NAFL remains unknown, the management of this condition is empirical. Treatment of patients with NAFL has typically been focused on the management of associated conditions such as obesity, diabetes mellitus, and hyperlipidemia as well as discontinuation of potentially hepatotoxic drugs known to produce NAFL.
Treatment of Associated Conditions Metabolic and Hereditary Conditions
A large body of clinical and epidemiological data gathered during the last three decades indicates that obesity and type 2 (non-insulin-dependent) diabetes mellitus are major associated conditions or predisposing factors leading to the development of NAFL. [1,[6] -9] Hence, it is reasonable to believe that the prevention or appropriate management of these conditions would lead to improvement or arrest of the liver disease.
NAFL may resolve with weight reduction, although the benefits of weight loss have been inconsistent. An early report described two patients whose biopsy showed file:///C|/Documents%20and%20Settings/One/Desktop/NASH052203/od8.html (3 of 16)1/25/2004 9:39:29 AM Treatment of Nonalcoholic Fatty Liver: Present and Emerging Therapies steatosis, necroinflammation, and fibrosis that significantly improved following 11 and 20 kg weight loss over 1 year. [10] In another report, five obese patients stopped eating for some time and lost 14-30 kg within 1 month. The hepatic fat content decreased in three of them, but fibrosis became more prominent in four of the five patients.
[11] In another series, 14 patients maintained a mean weight loss of nearly 65 kg for 1.5 years and in more than half the liver biopsy findings normalized. [12] Another case series of 39 obese patients reported a marked biochemical improvement, particularly in the patients who lost more than 10% of body weight. [13] Liver biopsies were not performed in any of these patients. In another series, [14] 41 morbidly obese patients with NAFL had a median weight loss of 34 kg during treatment with a very low calorie formula diet (388 kcal/day). The degree of fat infiltration improved significantly. However, a fifth of the patients, particularly those with more pronounced reduction of fatty changes and faster weight loss, developed slight portal inflammation or fibrosis. None of the patients losing less than 230 g per day or approximately 1.6 kg per week developed fibrosis. A significant improvement in liver biochemistries was noted regardless of the histological changes. In a more recent study, [15] liver biochemistries and the degree of fatty infiltration improved significantly in 15 obese patients with NAFL who were treated with a restricted diet (25 cal/kg/day) plus exercise for 3 months. Improvement in the degree of inflammation and fibrosis also occurred in some patients. Weight loss led to improvement in serum aminotrasferase levels and degree of hepatic steatosis evaluated by ultrasonography. Posttreatment liver histology normalized in the only child who underwent liver biopsy. In a more recent series, [17] 33 obese children with abnormal liver tests related to NAFL underwent 6 months of treatment with a moderately hypocaloric diet (mean 35 cal/kg/day; carbohydrates 65%, protein 12%, fat 23%) plus aerobic exercise (6 hours/week) to obtain a weight loss of about 500 g per week. Liver tests became normal in all children who lost weight, whereas the degree of steatosis evaluated by ultrasonography improved significantly or normalized in all children who lost 10% of body weight. In another report, [18] six obese children with NAFL had improvement in serum aminotransferases with weight loss after a mean follow-up of 18 months.
Thus, weight loss, particularly if gradual, may lead to improvement in liver histology.
However, rate and degree of weight loss required for normalization of liver histology have not been established. It seems that the means by which weight loss is achieved is important and may play a critical role in determining whether more severe liver damage will develop. In patients with a high degree of fatty infiltration, pronounced reduction of fatty changes and fast weight loss may promote portal inflammation and fibrosis. Similarly, starvation or total fasting may lead to development of pericellular and portal fibrosis, bile stasis, and focal necrosis. [11, 14] some patients may be due to increased circulating free fatty acid levels derived from fat mobilization and, thus, a greater rate of exposure of the liver to an unusually high amount of free fatty acids. Furthermore, liver tests, in particular serum aminotransferase levels, usually improve or normalize with weight loss and they are poor predictors of worsening of liver damage related to weight loss. Different caloric restrictions have been evaluated. A formula providing 600-800 cal/day with 45-100 g of high-quality animal proteins, less than 100 g carbohydrate, and less than 10 g fat in adults seems to be reasonable, particularly for patients who are 30% overweight. [19] This low-calorie diet has been recommended by some authors only after a more conventional 1200-calorie diet has been tried and proved unsuccessful. Diet to produce weight loss should always be prescribed in an individual basis and considering the patient's overall health. Patients who have obesity-related disease such as diabetes mellitus, hyperlipidemia, or cardiovascular disease require close medical supervision during weight loss to adjust the medication dosage as needed. Further studies are necessary to determine the most appropriate content of the formula to be recommended for obese patients with NAFL.
Medications used to reduce appetite result in weight reduction in many patients. [20] These medications are associated with rare but potentially serious side effects, including pulmonary hypertension. Polymyxin B, a nonabsorbable antibiotic that specifically binds to the lipid A-core region of lipopolysacharide [29] and metronidazole, [30] has been shown to improve significantly the degree of fatty infiltration and reduce the production of tumor necrosis factor in rats receiving total parenteral nutrition.
Drugs and Hepatotoxins
Several drugs and environmental exposure to some hepatotoxins ( Table 1) tests normalized or significantly improved after 6 months of treatment with UDCA at 10/mg/ kg/day in 13 patients with steatohepatitis. In the latest study,[33] 31 patients with nonalcoholic steatohepatitis were randomized to UDCA (10 mg/kg/day) plus low-fat diet or low-fat diet alone for 6 months. Normalization of liver tests was significantly more common among patients treated with UDCA plus diet than diet alone. On the basis of these promising results, a large scale, placebo-controlled trial of UDCA in NAFL patients is now under way.
Betaine, a normal component of the metabolic cycle of methionine, increases S-adenosylmethionine levels, which in turn protect the liver from ethanolinduced triglyceride deposition in rats.
[34] In a recent study, betaine at 20 g/day was given to eight patients with nonalcoholic steatohepatitis. After a year of treatment, a significant improvement in serum aminotrasferase levels was noted as well as a marked improvement in the degree of steatosis, necroinflammatory activity, and fibrosis. [35] N-Acetylcysteine is a glutathione prodrug that increases glutathione levels in hepatocytes, which in turn constrains hepatocyte production of reactive oxygen species and, hence, protects against oxidative stress in the liver. Recently, Given the slowly progressive nature of NAFL, hundreds of patients with this condition would need to be enrolled in prospective clinical trials and be followed up for a number of years, perhaps decades, in order to see a real effect of a medication on long-term survival. It may be unrealistic to believe that such a study is feasible and will be appropriately funded. The identification of NAFL patients at risk of progressing to end-stage liver disease may lead the "high-risk" patients who, in theory, are expected to derive the most benefit from medical therapy to enroll in therapeutic trials.
Future Directions
In order to develop effective medical therapy for patients with NAFL, further work is clearly needed to enhance our understanding of the pathogenesis and natural history of this condition. Some lines of evidence, albeit still inconclusive and some derived from studies of alcohol-induced liver disease, suggest that oxidative stress/lipid peroxidation, bacterial toxins, overproduction of TNF-, alteration of hepatocyte ATP stores, and Cyp2E1 enzyme activity may play a role in the genesis of NAFL.
Acute or chronic hepatic steatosis, regardless of the cause, is associated with lipid peroxidation, which seemed to increase with the severity of steatosis. [39] Malondialdehyde, an end product of lipid peroxidation, activates hepatic stellate cells, stimulating collagen production and fibrogenesis. Malondialdehyde may also contribute to inflammation by activating nuclear factor-kB (NF-kB), which regulates the quantification of hepatic iron is also recommended for patients with abnormal serum iron studies. If excessive iron and perhaps also the HFE gene mutation are shown in a patient with NAFL, serial phlebotomies, which may improve liver biochemistries, [51, 52] may be a therapeutic option.
Type 2 diabetes mellitus and obesity are well-known conditions associated with resistance to normal peripheral actions of insulin. Hepatic steatosis was found in 50% of patients with unexplained hepatic iron overload plus at least one of the components of the "insulin resistance syndrome" including truncal obesity, type 2 diabetes mellitus, and hypertriglyceridemia.
[53] Hence, it is reasonable to speculate that the use of medications that improve insulin sensitivity may benefit the liver disease of patients with NAFL associated with insulin resistance conditions. Thiazolidinediones are a new class of antidiabetic drugs that selectively enhance or partially mimic certain actions of insulin, causing an antihyperglycemic effect frequently accompanied by a reduction in circulating concentrations of insulin, triglycerides, and nonesterified fatty acids. [54] Troglitazone, a thiazolidinedione derivative, was given to six patients with nonalcoholic steatohepatitis for 2-4 months. 
